Announcement PDF The Calmer Co International Limited 24 Cansdale St, Yeronga Queensland 4104 ACN: 169 441 874 Doc 1418825171.2 17 August 2026 ASX RELEASE The Calmer Co. Secures Exclusive Global Distribution Agreement for Kava Extract Ingredients up to $25 million Brisbane, Australia – The Calmer Co. International Limited (ASX: CCO), a leading consumer packaged goods company specialising in kava and other natural products that promote relaxation and sleep support, is pleased to announce the execution of an Exclusive Distribution Agreement with a multinational ingredients company (the “Distributor”), securing exclusive global distribution rights for the Company’s range of kava extract ingredients. The Agreement grants the Distributor exclusive rights to distribute the Company’s kava extract ingredients across Australia, New Zealand, the United States, Canada and ASEAN markets. To retain exclusivity, the Distributor must comply with minimum purchase commitments of approximately A$25 million over the initial three-year term, including approximately A$5.5 million in the first year, representing a potentially significant new contracted revenue stream and validating the Company’s growing botanical ingredients business. Strategic Highlights • Exclusive Distribution Agreement executed with a multinational ingredients company for the Company’s kava extract ingredient range. • To maintain exclusivity, the Distributor must meet minimum purchase commitments of approximately A$25 million over the initial three-year term, including approximately A$5.5 million for the first year of the Agreement, increasing in years two and three. • Exclusive distribution rights granted across Australia, New Zealand, the United States, Canada and ASEAN markets, subject to meeting minimum purchase volumes. • Initial three-year term with two further three-year renewal options, subject to the Distributor meeting minimum purchase and payment conditions. • Establishes a co-branding arrangement for the Distributor’s ingredient brand on the Company’s finished products. • Incorporates standard commercial protections, including retention of title and periodic price review rights. Doc 1418825171.2 2 • Reinforces The Calmer Co.’s strategy of monetising its Pacific kava supply chain through high-value branded ingredient sales alongside its consumer products business. Securing a Global Distribution Partner for Kava Extract Ingredients Chief Executive Officer Zane Yoshida said the Agreement was an important strategic step in monetising the Company’s kava extract ingredients through a globally established distribution partner. “This agreement represents a major validation of our botanical ingredients strategy. Securing a multi-year distribution commitment from a multinational ingredients company gives us confidence in the global demand for our kava extract range and provides a substantial, contracted revenue stream over the coming years.” “Importantly, this agreement complements the strategic initiatives we have announced over recent months, including our expanding Pacific supply chain and manufacturing capability. It reflects our disciplined approach to building an integrated Pacific kava business capable of delivering long-term value for shareholders.” The Agreement adds a new, exclusive global distribution channel for the Company’s kava extract range, alongside its existing wholesale ingredients customer base, which is preserved under agreed carve-out arrangements. Together, these relationships provide the Company with a diversified, high-value ingredients sales channel supporting its broader kava value chain strategy. Exclusive Distribution Agreement Under the Agreement, the Distributor has been granted exclusive rights to distribute the Company’s range of kava extract ingredients, including water-extracted and CO2-extracted Noble Kava products, across the Territory, subject to the Distributor meeting agreed annual minimum purchase requirements. To maintain the exclusivity granted under the Agreement, the Distributor must meet minimum purchase requirements totalling approximately A$25 million over the initial three-year term, including approximately A$5.5 million in the first year, increasing in years two and three as minimum volumes grow. The Distributor is part of a multinational ingredients group specialising in plant-derived and natural healthcare ingredients, supplying botanical, nutritional and plant-based raw materials into the dietary supplements, sports nutrition and complementary medicines markets, with distribution across more than 60 countries, reflecting its scale and standing as a strategic distribution partner for the Company’s ingredients business. Doc 1418825171.2 3 The Agreement includes a periodic price review mechanism, enabling the Company to review and amend pricing by notice every twelve months, together with retention of title and security interest provisions over unpaid stock, providing the Company with enhanced payment security. In addition to the commercial terms, the Agreement incorporates agreed product specifications and quality warranties, together with mutual rights of inspection, enabling the Company to inspect the Distributor’s storage facilities and the Distributor to inspect the Company’s production facilities, as well as co-branding provisions allowing the Distributor’s ingredient brand to be featured on the Company’s finished products on an “ingredient inside” basis, further strengthening the commercial relationship between the parties. Supporting the Company’s Wholesale (Bulk Ingredients) Pillar The Agreement complements The Calmer Co.’s existing kava extract ingredients business and directly supports Wholesale (Bulk Ingredients), one of the Company’s four key strategic pillars, by building high-value, contracted revenue streams from its integrated Pacific kava supply chain. By securing a contracted, multi-year distribution partnership with a multinational ingredients company, the Company is diversifying its revenue base beyond branded consumer products into higher-margin, wholesale botanical ingredient sales. The Company’s growing portfolio of kava extract ingredients, including water-extracted and CO2-extracted Noble Kava products sourced from Fiji, Papua New Guinea and Vanuatu, now benefits from a committed global distribution channel, reducing reliance on direct wholesale sales alone. CO2 extraction capacity to support anticipated volumes under the Agreement is expected to be provided through the Company’s existing specialist extraction partners in Australia and India, as previously disclosed to the market, together with the advanced supercritical CO2 extraction capability being added in Fiji under the Company’s manufacturing partnership with Kaiming Agro Processing. The Agreement complements the Company’s previously announced supply and manufacturing initiatives, including its Pacific sourcing agreements and Heads of Agreement with Kaiming Agro, by providing a committed, high-value sales channel for the Company’s expanding kava extract ingredient range. Connecting Pacific Supply with Global Distribution This Agreement builds directly on the Company’s recently announced Strategic Supply Agreement with a leading Pacific-based supplier of premium noble kava, which secured reserved minimum monthly supply capacity of premium noble kava from Papua New Doc 1418825171.2 4 Guinea and Vanuatu with an indicative annual supply value of approximately A$8.65 million. Together, the two agreements connect the upstream and downstream ends of the Company’s kava extract ingredients business, securing long-term access to premium raw material supply on one hand, and a committed, multi-year global distribution channel for the resulting ingredients on the other, reflecting continued execution of The Calmer Co.’s strategy to build an integrated Pacific kava business spanning sourcing, manufacturing and global commercialisation. Quality Assurance Framework Maintaining consistent quality remains central to The Calmer Co.'s commercial strategy. These quality systems are designed to support customer confidence across the Company’s growing wholesale ingredients business while reinforcing the Company’s reputation as a supplier of premium Pacific kava extracts. Strategic Significance This Agreement reflects an important step in the execution of the Company’s Wholesale (Bulk Ingredients) strategic pillar, and in the Company’s evolving, vertically-integrated operating model across the Pacific kava value chain, from diversified grower relationships in Fiji, Papua New Guinea and Vanuatu, through scientific quality assurance via the Company’s GC-MS laboratory capability, advanced manufacturing through strategic partners including KAPPL, to global commercialisation of both branded consumer products and, now, exclusively distributed botanical ingredients through this Agreement. This model allows The Calmer Co. to secure reliable access to global distribution channels and downstream commercial relationships through strategic partnerships, while concentrating the Company’s own capital and management focus on product innovation, supply chain integration and brand-building. ASX Compliance Disclosure Pursuant to ASX Compliance Update 02/25, the Company: • does not consider the identity of the Distributor to the Agreement to be information that a reasonable person would expect to have a material effect on the price or value of the Company’s securities; • confirms that this announcement contains all material information relevant to assessing the impact of the Agreement on the price or value of the Company's securities, and is not misleading by omission; and Doc 1418825171.2 5 • confirms that it has conducted due diligence enquiries into the Distributor and is satisfied with its standing and creditworthiness to perform its obligations to the Company. Please interact with management about this announcement via Investor Hub Link here: This announcement has been approved by the Board of Directors. ends For further information Investor & Media Relations Zane Yoshida investors@thecalmerco.com About The Calmer Co. The Calmer Co. International Limited (ASX:CCO) is a fast growing beverage business leveraging a global opportunity in kava and other natural products that replace alcohol and support relaxation and sleep. Our products are delivered to consumers globally through e-commerce channels and blue- chip retail distribution partners, supported by a reliable farm to shelf supply chain. The product range includes drinking powders, natural and flavoured kava shots, concentrates and capsules, sold under the brands Fiji Kava® , Taki Mai® and Danodan Hempworks in markets including USA, Australia, New Zealand, China and the Pacific Islands. Forward looking statements This ASX release includes certain forward-looking statements that are based on information and assumptions known to date and are subject to various risks and uncertainties. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. Such forward- looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of the Company. These factors may cause actual results to differ materially from those expressed in the statements contained in this announcement.